Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PBMC and GM-CSF immunotherapy with radiofrequency ablation for hepatocellular carcinoma
2008-003925-17Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim and autologous G-CSF mobilized peripheral blood mononuclear cells in hepatocellular carcinoma (HCC), sponsored by Azienda Ospedaliero-Universitaria di Parma. Started Feb 2009; status: completed.
02
Drugs
sargramostimautologous G-CSF mobilized peripheral blood mononuclear cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-003925-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003925-17.